Tempero Bio has hit the brakes on a phase 2-stage alcohol use disorder (AUD) candidate while the biotech considers its options, according to the program’s partner. | Tempero Bio has hit the brakes on ...
NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora’s M4 franchise; both programs have potential best-in-class pharmacology No convulsions observed in pre-clinical ...
Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule ...
Neurocrine Biosciences has penned a deal with China’s TransThera Sciences potentially worth more than $880 million in biobucks for inhibitors aimed at a red-hot inflammation target. | Neurocrine ...
Ivana Magovčević-Liebisch President and CEO, Dr Magovčević-Liebisch is an accomplished pharmaceutical and biotechnology executive with over 25 years of leadership experienceDr Ruth McKernan FMedSci ...
The CALIBRATE study of encaleret for patients with ADH1 met all pre-specified primary and key secondary efficacy endpoints - ...
Despite regulatory progress in many countries, skepticism and a lack of robust randomized trials continue to limit the use of medical cannabis in rheumatology.
Phase 1 dose escalation trial in SMARCA4 (BRG1)-mutated cancer remains on track with non-small cell lung cancer ...
New research reveals how tiny electrical gates in the brain, known as NMDA receptors, control learning, memory, and neuron ...
New study shows that targeting an oft-drugged family of cell membrane receptors with biased modulators can expand potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback